Resources

Select from the drop-down menu below to read the most up-to-date news about pelareorep.

October 23, 2023 | Poster
Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients – Results from the GOBLET study
Arnold, Dirk et al. Previously presented at ESMO Congress 2023, Oct. 23, 2023
October 23, 2023 | Poster
Pelareorep + atezolizumab and chemotherapy in third-line (3L) metastatic colorectal cancer (mCRC) patients – Interim results from the GOBLET study
Ungerechts, Guy et al. Previously presented at ESMO Congress 2023, Oct. 22, 2023
October 3, 2023 | Poster
Multiplex analysis of the tumor immune microenvironment during treatment with atezolizumab/pelareorep/letrozole reveals novel immune-tumor interactions
Dadrastoussi, Homa et al.
June 2, 2023 | Poster
BRACELET-1 (PrE0113): Inducing an Inflammatory Phenotype in Metastatic HR+/HER2- Breast Cancer with the Oncolytic Reovirus Pelareorep in Combination with Paclitaxel and Avelumab
Clark, Amy et al. Previously presented at the 2023 ASCO Annual Meeting; 2023 Jun 2-6.
June 2, 2023 | Poster
Efficacy of Function-enhanced, Re-activatable, Dual-specific CAR T cells Pre-loaded with Oncolytic Virus for Immunotherapy of High-Grade Glioma
Webb, Mason et al. Previously presented at the 2023 ASCO Annual Meeting; 2023 Jun 2-6.
December 1, 2022 | Poster
A multicenter, single-arm, open-label Phase I study of AN1004 (Pelareorep) oncolytic virus plus paclitaxel inChinese patients with Hormone receptor-positive and HER2-negative advanced/metastatic breast cancer (REO 026-1)
Li, Wei et al, Previously presented at the 2022 San Antonio Breast Cancer Symposium®; December 6-10, 2022
December 1, 2022 | Poster
Pelareorep primes the tumor for checkpoint inhibition therapy by activating the interferon-gamma signaling pathway andtumor inflammation signature in early breast cancer patients – results of the AWARE-1 trial
H. Loghmani, J Gavila, L. Manso, R. Trauger, F. Salvador, T. Pascual, A. Prat, Matt Coffey, T. Heineman
November 10, 2022 | Media Coverage
Oncolytics Presents Promising Pancreatic Cancer Data at SITC

Expanded Access

Oncolytics believes that participating in clinical trials is the best way for patients to access pelareorep. We are not currently able to fulfill expanded access requests at this time.

Information on many of Oncolytics clinical trials can be found at ClinicalTrials.gov. If a treating doctor would like additional information, the doctor should formally contact Oncolytics at info@oncolyticsbiotech.com.

Contact Us

For questions regarding our science, partnership opportunities, or other inquiries, we encourage you to reach out.

Get in touch